NCT04213209Completed
Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"
Special Drug Use Surveillance for Adcetris Intravenous Infusion 50 Milligrams "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Hodgkin Lymphoma (Only Pediatric Patients)"
Source: ClinicalTrials.gov · Last updated 27 Sept 2024
Brief summary (registry, in English)
The purpose of this survey is to examine the safety of adult patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma (PTCL) (excluding anaplastic large cell lymphoma (ALCL)) and pediatric patients with relapsed or refractory CD30-positive PTCL or Hodgkin lymphoma (HL) in the actual use of on concomitant Brentuximab Vedotin in routine clinical practice.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 95 (actual)
- First submitted
- 25 Dec 2019
- Start date
- 14 Feb 2020
- Primary completion date
- 13 Dec 2023
- Lead sponsor
- Takeda
- Diseases
- Childhood cancers
- NCT number
- NCT04213209
What you commit to
- Study type: Observational
- Participants enrolled: 95
- From 14 Feb 2020 to the primary completion date, 13 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Participants with a history of severe hypersensitivity to Brentuximab Vedotin.
Other
- Participants taking bleomycin hydrochloride treatment.
Who the study is looking for
- Participants with relapsed or refractory lymphoma.
- CD30-positive participants.
- Participants who receive study drug after obtaining approval of CD30-positive PTCL indication of study drug.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Tokyo | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.